Frazier Life Sciences Management’s Verona Pharma VRNA Stock Holding History

Frazier Life Sciences Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,383,950	Closed	-$361M	–	52
2025 Q3	$361M	Hold	3,383,950	–	–	10.82%	3
2025 Q2	$320M	Sell	3,383,950 -73,900	-2%	-$5.47M	12.8%	2
2025 Q1	$220M	Buy	3,457,850 +73,900	+2%	+$4.42M	10.03%	3
2024 Q4	$157M	Hold	3,383,950	–	–	6.52%	3
2024 Q3	$97.4M	Buy	3,383,950 +69,601	+2%	+$1.71M	3.9%	8
2024 Q2	$47.9M	Buy	3,314,349 +300,000	+10%	+$4.38M	2.24%	13
2024 Q1	$48.5M	Hold	3,014,349	–	–	2.05%	16
2023 Q4	$59.9M	Hold	3,014,349	–	–	3.2%	9
2023 Q3	$49.1M	Buy	3,014,349 +70,000	+2%	+$1.35M	3.26%	9
2023 Q2	$62.2M	Hold	2,944,349	–	–	3.72%	9
2023 Q1	$59.1M	Buy	2,944,349 +128,629	+5%	+$2.78M	4.28%	9
2022 Q4	$73.6M	Buy	2,815,720 +716,179	+34%	+$9.54M	4.57%	10
2022 Q3	$21.5M	Buy	+2,099,541	New	+$17.7M	1.65%	19

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Frazier Life Sciences Management's VRNA Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 3,383,950 shares — an estimated $361M sold.

Frazier Life Sciences Management first reported a position in VRNA in Q3 2022 and held it in 13 quarters. The position peaked at $361M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Frazier Life Sciences Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 3,383,950 Verona Pharma shares in Q4 2025, an estimated $361M.
Frazier Life Sciences Management first reported a position in Verona Pharma in Q3 2022 and held it in 13 quarters.
Frazier Life Sciences Management's Verona Pharma position peaked at $361M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.